1 / 33

HIV-1 Resistance - Implications For Clinicians

HIV-1 Resistance - Implications For Clinicians. Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina. Overview of Presentation. HIV-1 resistance to ARV; a consequence of viral replication and HIV biology Suppression of HIV replication limits resistance

apria
Télécharger la présentation

HIV-1 Resistance - Implications For Clinicians

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina

  2. Overview of Presentation • HIV-1 resistance to ARV; a consequence of viral replication and HIV biology • Suppression of HIV replication limits resistance • Clinical indications for resistance testing • Genotype vs. phenotype • Clinical Importance of transmitted resistance • Multiple causes of virologic failure of ART • Resistance testing is one key to successful therapy in the treatment experienced patient • Novel agents – novel resistance

  3. Resistance Is a Matter of Degree

  4. Suppression of Replication Limits Resistance Incidence of Resistance Decreasing with use of HAART

  5. Types of Resistance Tests • Genotype • HIV gene sequencing of the patient’s virus to detect mutations known to confer drug resistance • Phenotype • Measures ability of a recombinant virus derived from the patient sample to grow in different concentrations of antiretroviral drugs Hirsch et al. Clin Infect Dis. 2003;37:113-28.

  6. Interpretation of Genotypic Assays • Is an indirect measure of resistance • Requires knowledge of which mutation are associated with a change in susceptibility • Expert advice • May not be available • Experts’ views may be inconsistent • Rules-based algorithms • Provided by most labs, third-party sites • Need regular updating • Virtual Phenotype (VircoType) • Phenotypic information using genotype • Database of matched genotypes and phenotypes

  7. 0 Provider Knowledge of Specific Resistance Mutations N = 100 % Providers RecognizingSpecific Mutations Mutations Salama et al. Clin Infect Dis. 2003;36:101-4.

  8. Phenotypic SusceptibilityRelationship Between Drug Concentration and Viral Inhibition 100 Wild-type Resistant 50 Inhibition of Virus Replication (%) Fold resistance 0 Wild-type IC50 Resistant IC50 Drug Concentration

  9. Interpretation of Phenotypic Assays • Results reported as IC50 or fold-change (FC) compared with IC50 of wild-type virus • Individual results provided for each drug • Thresholds to define reduced susceptibility • Biologic cutoff: based on biologic variations in treatment-naive patients (usually 2 SD > median) • Clinical cutoff: • As good as clinical data used to estimate cut points • Resistance is a continuum – precise breakpoints unlikely • Two relevant breaks? • Decreased response and • Minimal response

  10. Clinical Indications for Resistance Testing

  11. Current Guidelines for Resistance Testing * Only if mother is viremic ** Only if mother was viremic and on treatment at time of birth 1. DHHS. Guidelines. Oct 10, 2006. 2. Hirsch et al. Clin Infect Dis. 2003;37:113-28. 3. Vandamme et al. Antivir Ther. 2004;9:829-48.

  12. Transmitted ARV Resistance Clinically Important in the Developed World Surveillance Essential in the Developing World

  13. How Common is Drug Resistance at Diagnosis? • US Variant, Atypical and Resistant HIV Surveillance System (VARHS) • Estimate prevalence of transmitted resistant mutations • Determine distribution of HIV subtypes • March 2003 to October 2006; 11 states, 409 sites, n=3130 10% 6.9% M41L 45.1% of NRTI K103N 70.1% of NNRTI L90M 40.0% of PI 95% Subtype B 5% 3.6% 2.4% 1.9% MDR Any NRTI NNRTI PI Wheeler et al. 14th CROI. Los Angeles, 2007. Abs 648

  14. FTC-301A: Impact of Baseline Resistance on Treatment Outcome Naive pts, baseline VL > 5000 copies/mL Incidence (%) of Virologic Failure Mutation type: FTC + ddI + EFV (n=270) d4T + ddI + EFV (n=276) Borroto-Esoda et al. 11th CROI, 2004. Abs 672.

  15. How Important Are Minority Variants?

  16. Standard Genotype 181C 108I 190A 103N

  17. Antiretroviral Response Following sdNVP Lockman et al. NEJM 2007;356:135-47.

  18. Resistance and Virologic Failure Multiple Causes of Virologic Failure Replication in the Presence of Antiretrovirals Results in Resistance

  19. 0 0 Treatment-Experienced Patients: ARV Treatment Failure Social/personal issues Poor adherence Regimen issues Toxicities Insufficient drug level Poor potency Rapid clearance Wrong dose Pre-existing resistance Host genetics Poor activation Poor absorption Drug interactions Viral replication in the presence of drug Resistant virus Resistant virus ART resistance testing. National resource center. Available at: http://www.aidsetc.org/aidsetc?page=et-01-00. Accessed November 29, 2006.

  20. Impact of Suboptimal Adherence Partially effective regimen Resistance Highly effective regimen Adherence Bangsberg et al. AIDS 2003;17:1925-32.

  21. Resistance Testing in Treatment Experienced Patients • Detectable plasma HIV RNA on therapy • First Question ‘Is it time to switch therapy?’ • Obtain resistance testing • The greater the resistance the more useful phenotype or virtual phenotype • Assess clinical situation • Adherence • Previous treatment history – ARV tolerability and toxicity • Balance clinical urgency with availability of active agents including new drugs and expanded access • New agents – especially those in a new class are likely to have the most activity

  22. With New Agents in Existing Classes (PI and NNRTI) Resistance Patterns Are More Complex Darunavir (DRV) Tipranavir (TPV) Etravirine (ETV)

  23. New Agents in Existing Classes • Mutations to older agents are likely to be present • Majority variants • Minority variants • Some degree of cross resistance can be anticipated • Cross resistance increases with the number and type of mutations • The activity of a new agent from a new class is likely to be more predictable even with state of the art resistance testing

  24. TORO Studies - Enfuvirtide *p<0.05 DC+Switch=Failure * * * * * ENF+OB: 98 179 152 83 27 OB: 49 88 84 46 16 Miralles et al. AIDS 2005;19:2178-9. Lalezari et al. NEJM 2003;348:2185-85. Lazzarin et al. NEJM 2003;348:2186-95.

  25. TORO Studies - Enfuvirtide *p<0.05 DC+Switch=Failure * * * * * ENF+OB: 98 179 152 83 27 OB: 49 88 84 46 16 Miralles et al. AIDS 2005;19:2178-9. Lalezari et al. NEJM 2003;348:2185-85. Lazzarin et al. NEJM 2003;348:2186-95.

  26. TORO Studies - Enfuvirtide *p<0.05 DC+Switch=Failure * * * * * ENF+OB: 98 179 152 83 27 OB: 49 88 84 46 16 Miralles et al. AIDS 2005;19:2178-9. Lalezari et al. NEJM 2003;348:2185-85. Lazzarin et al. NEJM 2003;348:2186-95.

  27. Resistance Defines an Active Antiretroviral Agent CCR5 Inhibitors Integrase Inhibitor

  28. CCR5 Inhibitors • HIV-1 entry into CD4 cells is dependent on a second receptor: CCR5 (R5 viruses) or CXCR4 (X4 viruses) • Early in HIV disease course most individuals have only R5 virus detectable • In more advanced disease and highly treatment experienced patients dual tropic virus or mixtures of R5 and X4 viruses are more common • CCR5 Inhibitors bind to host receptor (CCR5) blocking entry • Maraviroc and vicriviroc • Both have shown substantial activity in patients

  29. NSI virus predominates early in disease Dual/mixed virus detected in approximately 50% of patients over time CD4+ cell count decline accelerates following detection of SI in patients in whom NSI-only virus was previously detected Will emergence of X4 variants on R5 inhibitor therapy lead to CD4 cell decline? Association Between Emergence of SI Virus and CD4+ Cell Count 800 600 Mean (SE) CD4+ Cell Count (cells/mm3) 400 NSI 200 NSI → SI SI 0 -48 -36 -24 -12 0 12 24 36 Time (Months) Koot et al. Ann Intern Med. 1993;118:681-688.

  30. HIV-1 Resistance to CCR5 Antagonists • Two mechanisms • Selection for (emergence of) viral variants that use CXCR4 (dual tropic viruses or mixed populations) • Occurs about 2/3 of the time • As yet NOT associated with rapid fall in CD4 cell count • Alterations (mutations) in HIV gp 120 • No Change in viral tropism • Allows virus to use CCR5 with inhibitor bound • Plateau in antiviral effect as opposed to change in IC50 • The drug is unable to fully inhibit virus regardless of concentrations achieved

  31. Integrase Inhibitors • Integrase mechanism has 3 steps • Association with dsHIV DNA – pre-integration complex • 3’ processing by integrase enzyme • Strand transfer of HIV DNA into host chromosome • Potent inhibitors of stand transfer now in development • Raltegravir – Phase III studies recently presented • Elvitegravir – Phase II studies

  32. Integrase Inhibitor Resistance • Primary mutations surround the catalytic site • Raltegravir • Resistance emerged in 3/4 patients with virologic failure who had genotype results • Two major pathways with apparent primary mutations but one or more additional mutations • Likely compensatory for fitness • Cross resistance between integrase inhibitors is not yet known

  33. Summary • Antiretroviral resistance is a consequence of HIV replication and defines an active antiretroviral • Resistance Impacts all stages of antiretroviral treatment typically with increasing complexity with increasing antiretroviral treatment experience • In treatment experienced patients resistance information guides regimen selection but also influences the timing of therapy switch • New agents with new mechanisms present challenges for the identification, quantification and clinical impact of resistance

More Related